Federal rescheduling changed the tax question, but it didn’t answer all of it. If you’re buying, selling, or raising money on a cannabis company in 2026, the biggest single variable in cannabis rescheduling business valuation is now how Section 280E applies to a store’s licensed inventory, including sales to adults at dual-licensed stores. That question is contested and unresolved, so a deal has to price more than one outcome.
This guide to cannabis rescheduling business valuation covers what actually changed, why it moves price, and the diligence questions that separate a real medical premium from a seller’s wishful spreadsheet.
Cannabis Rescheduling Business Valuation Starts Here: What the Order Actually Did
In April 2026 the Justice Department issued a final order, published in the Federal Register on April 28, 2026, moving two categories of marijuana from Schedule I to Schedule III: marijuana in drug products that have cleared FDA review, and marijuana subject to a state medical marijuana license. You can read the order on the Federal Register.
Other marijuana stayed in Schedule I. The order never uses the words “adult-use” or “recreational,” though it says DEA registrations don’t authorize dispensing “for non-medical purposes.” How it applies to licensed inventory sold to adults is disputed. DEA held a hearing on broader rescheduling from June 29 through mid-July 2026, and as of late September the administrative law judge’s recommended decision was still pending. So the tax treatment is unsettled today and could change later, which is why any cannabis rescheduling business valuation done this year needs a plan for more than one outcome. Our federal cannabis rescheduling 2026 explainer tracks the process, and Cannabis Legalization News covered the hearing as it happened.
How Does Cannabis Rescheduling Change Business Valuation?
It changes after-tax cash flow, and buyers pay for after-tax cash flow. Section 280E of the tax code only disallows deductions for businesses trafficking in Schedule I or II substances. Marijuana “subject to a state medical marijuana license” is now in Schedule III. The IRS has described that as marijuana “sold pursuant to” a medical license. The listing doesn’t say that, and whether licensed inventory stays in Schedule III when sold to an adult is contested. No court has decided the tax question, although the Sixth Circuit said in a contract case that the rescheduling applies “only to medical marijuana.”
Read the statute yourself at 26 U.S.C. § 280E. It’s one sentence long and it has been eating cannabis margins for years. For cannabis rescheduling business valuation, that’s the whole ballgame: identical gross revenue can produce very different net income depending on how that question comes out.
The Treasury Announcement That Drives the Numbers
On April 23, 2026, Treasury and the IRS said they plan to issue guidance after the order. As of October 31, 2026, we haven’t seen it issued. Two announced points matter for deal pricing:
- Full-year transition. Rescheduling generally will be treated as applying for a business’s full taxable year that includes the order’s effective date. If that holds, a calendar-year operator’s covered activity could get relief for all of 2026, not just the months after April.
- Apportionment for mixed businesses. For businesses with multiple activities, 280E applies only to the activities tied to Schedule I or II trafficking, “e.g., by apportioning expenses.”
That second point is where cannabis rescheduling business valuation gets interesting. A dual-licensed company may face an allocation if the narrower reading holds, and allocations are only as good as the books behind them. We walk through the tax history in 280E retrospective relief for medical marijuana.
Pricing a deal around this question? Talk to our cannabis M&A counsel before the letter of intent locks in a number you can’t defend.
Why a Medical License Could Be Worth More in a Cannabis Rescheduling Business Valuation
Take two dispensaries with the same revenue and the same operating costs. One holds a state medical license. The other holds only an adult-use license. A buyer may reasonably price those stores differently, because the first has the stronger Schedule III argument. Neither result is settled. That is cannabis rescheduling business valuation in a nutshell.
How big the gap is depends on the target’s cost structure and on how the tax question comes out, so we won’t pretend there’s a universal multiple. In our core states it plays out differently:
- Florida. The market is medical-only after the 2024 adult-use amendment fell short of the 60% it needed, so the dual-license question doesn’t arise there the same way. See our Florida MMTC license transfer guide for how those deals close, and the state’s Office of Medical Marijuana Use for the program itself.
- Illinois. Starting September 10, 2026, adult-use dispensaries can apply for a Medical Cannabis Dispensing Organization “15-37 License” under 410 ILCS 705/15-37, with a $5,000 application fee, per the IDFPR adult-use cannabis program. A store that adds a medical license changes the diligence, because a buyer will want to see its license dates, supply records and how each sale is coded. CLN has the application details.
- Michigan. The state still licenses medical facilities separately under the MMFLA through the Cannabis Regulatory Agency, so which license a Michigan target actually sells under deserves a hard look.
For the operator-side view of what a medical license is worth, Collateral Base looks at medical license value under Schedule III.
Five Diligence Questions for Cannabis Rescheduling Business Valuation
A seller claiming a medical premium should be able to answer all five of these with documents, not adjectives.
1. What licenses cover the inventory and the revenue?
The order covers marijuana “subject to a state medical marijuana license.” Pull the licenses, the supplier transfer records and the point-of-sale data. A store that sells mostly to adults while holding a medical license is exactly where the dispute sits, so price it with that uncertainty in view.
2. Can the books support an expense allocation?
If the target runs both programs and the narrower reading holds, someone may have to split shared costs between medical and adult-use. Ask how the target plans to do it and whether its accounting system can prove it. A clean allocation is worth money. A guess is a future audit.
3. Does the target have its DEA registration, and will it survive the deal?
Schedule III activity requires DEA registration, and the new rules give state medical licensees an expedited path. But a DEA registration can’t be assigned or transferred without DEA’s written consent under 21 CFR 1301.52(b). In an asset deal, plan for the buyer to need its own. That’s a new closing condition most cannabis purchase agreements weren’t written to handle.
4. What tax positions has the target already taken?
Has the target filed returns claiming deductions, or amended prior returns? Those positions become the buyer’s problem in a stock or membership-interest deal. Tax reps, a specific indemnity, and escrow sized to the exposure belong in the agreement.
5. What happens to the price if the law moves again?
If broader rescheduling moves all marijuana into Schedule III, today’s medical premium shrinks. If the order is narrowed or challenged, it could grow or reverse. Don’t pay a fixed premium for a variable fact. Earn-outs, price adjustments tied to regulatory events, or a lower base price with upside all let the deal flex with the law.
Structuring Around the Uncertainty
The smartest 2026 deals run cannabis rescheduling business valuation under more than one tax scenario, including one where medical and adult-use cash flow are treated differently and one where licensed inventory is treated the same. Then the purchase agreement assigns who carries each risk.
That usually means separate revenue schedules in the reps, a DEA registration covenant, tax indemnities that survive closing, and the usual state change-of-ownership approval as a condition. The state approval side hasn’t changed; our cannabis license transfer rules by state hub covers who approves what. The diligence checklist on our cannabis due diligence attorney page is the place to start the document request.
Frequently Asked Questions
Is a medical cannabis license worth more than an adult-use license after rescheduling?
In most cannabis rescheduling business valuation work, often yes, because marijuana subject to a state medical marijuana license is listed in Schedule III. How that applies to sales to adults is contested. The size of the premium depends on the business’s costs, its records and how that question comes out.
Does 280E still apply to dual-licensed dispensaries?
That’s contested. No court has decided the tax question, although the Sixth Circuit said in a contract case that the rescheduling applies “only to medical marijuana.” Treasury has said guidance is expected to apply 280E, for businesses with multiple activities, only to the Schedule I or II activity, for example by apportioning expenses. It hasn’t said how a dual-licensed store’s sales to adults are classified, and the guidance hasn’t been issued.
Does a buyer inherit the seller’s DEA registration?
Not automatically. Under 21 CFR 1301.52(b), a DEA registration cannot be assigned or transferred without DEA’s written consent, so buyers should plan for their own registration or for consent as a closing condition.
Could the medical valuation premium disappear?
It could shrink. DEA’s hearing on broader rescheduling finished in July 2026 and a decision is pending. If all marijuana moves to Schedule III, any tax gap between the two narrows.
The Bottom Line
Rescheduling opened a tax question that hasn’t been answered, and price follows tax. Cannabis rescheduling business valuation now has to carry that uncertainty. Buyers should demand proof of what they’re paying for; sellers with clean books should be ready to show it. Either way, get cannabis M&A counsel involved before the valuation becomes a signed number.
This article is general information about cannabis business law and federal tax developments as of October 31, 2026. No tax result is promised. It is not legal or tax advice, and reading it does not create an attorney-client relationship. Rescheduling and IRS guidance are still developing; confirm current law and consult a qualified tax advisor before acting. Howard Law Group advises cannabis clients in Illinois, Missouri, Wisconsin, Michigan, Ohio, New York and Florida.
